Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for cancer therapy–induced thrombocytopenia in hematologic malignancies
ChiCTR2400093333Phase 4Not yet recruiting
- Sponsor
- Henan Provincial People's Hospital
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in Thrombocytopenia, lymphoma and multiple myeloma (MM), sponsored by Henan Provincial People's Hospital. Primary endpoint: Proportion of patients who produce an efficacy response. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenialymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400093333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093333.